Tandem Diabetes Care (NASDAQ:TNDM) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS
by Doug Wharley · The Cerbat GemTandem Diabetes Care (NASDAQ:TNDM – Get Free Report) issued its earnings results on Thursday. The medical device company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.16, FiscalAI reports. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The business had revenue of $247.22 million for the quarter, compared to the consensus estimate of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The business’s quarterly revenue was up 5.5% compared to the same quarter last year.
Here are the key takeaways from Tandem Diabetes Care’s conference call:
- Tandem reported strong Q1 results with more than 29,000 pump shipments and $247 million in sales, and management is reaffirming 2026 guidance.
- The company has begun its PayGo pharmacy rollout, achieving ~40% formulary coverage early and
- Product momentum accelerated: Mobi now supports Android in the U.S., Control‑IQ+ cleared for use in pregnancy (first AID cleared for pregnancy in the U.S.), Libre 3 Plus and Dexcom G7 integrations planned, international Mobi launch in Q2, and a Mobi Tubeless 510(k) filing and a pivotal fully closed‑loop study are on track.
- Infusion set supplier shortages created modest supply‑sales pressure and meaningful customer impact for affected SKUs, with the company expecting disruption to persist into Q2 and some $3M–$4M timing headwinds from the international go‑direct transition.
- Margins and balance sheet strengthened: Q1 non‑GAAP gross margin was 55% (a Q1 record), adjusted EBITDA improved, the company generated $5M free cash flow and ended the quarter with $570M in cash (including $276M net proceeds from convertible debt), supporting execution of strategy.
Tandem Diabetes Care Price Performance
NASDAQ TNDM traded up $0.44 during mid-day trading on Thursday, hitting $18.47. The stock had a trading volume of 2,622,228 shares, compared to its average volume of 1,653,314. The company has a 50 day simple moving average of $21.32 and a 200 day simple moving average of $20.33. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.02 and a beta of 1.64. Tandem Diabetes Care has a 52-week low of $9.98 and a 52-week high of $29.65. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Tandem Diabetes Care by 30.5% in the 1st quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company’s stock valued at $4,054,000 after acquiring an additional 49,408 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tandem Diabetes Care by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company’s stock valued at $1,426,000 after purchasing an additional 2,096 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Tandem Diabetes Care by 41.1% in the first quarter. Millennium Management LLC now owns 227,585 shares of the medical device company’s stock valued at $4,361,000 after purchasing an additional 66,245 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $225,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Tandem Diabetes Care by 5.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company’s stock worth $13,653,000 after purchasing an additional 34,069 shares in the last quarter.
Wall Street Analysts Forecast Growth
TNDM has been the subject of a number of recent analyst reports. Piper Sandler upgraded shares of Tandem Diabetes Care from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $33.00 in a research report on Tuesday, March 17th. UBS Group reissued a “neutral” rating and issued a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. Mizuho set a $22.00 price target on Tandem Diabetes Care and gave the company a “neutral” rating in a research note on Friday, February 20th. Stifel Nicolaus upped their price objective on Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Friday, February 20th. Finally, Lake Street Capital raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of “Moderate Buy” and an average target price of $30.05.
View Our Latest Report on TNDM
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.
The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.